Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RALL-2016m Study for Ph-negative ALL
NCT06237192Recruiting
- Sponsor
- National Medical Research Center for Hematology
- Start
- Apr 2023
- Primary completion
- Sep 2026
- Modality
- Antibody Conjugates, scFv Fragments, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of blinatumomab and venetoclax in acute lymphoblastic leukemia (ALL), sponsored by National Medical Research Center for Hematology. Primary endpoint: Disease-free survival at 3 years. Started Apr 2023; status: recruiting.
02
Drugs
blinatumomabvenetoclax
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06237192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06237192.